Loss Per Share (Tables)

6 Months Ended

Jun. 30, 2024

Earnings Per Share [Abstract]

Schedule of Weighted Average Number of Ordinary Shares Outstanding and The Effect of Dilutive Ordinary Share

Diluted loss per share is based on dividing the loss attributable for the year, adjusted for the effect of dilutive ordinary shares, by ordinary share equivalents, which includes the weighted average number of ordinary shares outstanding and the effect of dilutive ordinary share equivalents.

	Three Months Ended June 30,						Six Months Ended June 30,
	2024			2023			2024			2023
	($'000, except share and per share amounts)			($'000, except share and per share amounts)			($'000, except share and per share amounts)			($'000, except share and per share amounts)
Net loss	$	(12,255	)	$	(1,751	)	$	(21,208	)	$	(13,827	)
Net loss per share - basic and diluted	$	(0.02	)	$	(0.00	)	$	(0.03	)	$	(0.02	)
Weighted-average number of shares used in computing net loss per share - basic and diluted		711,770,804			628,421,064			706,407,371			626,185,695

Schedule of Potentially Dilutive Shares Were Not Included In The Calculation of Diluted Shares Outstanding.

The Company excluded the following potentially dilutive ordinary shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect:

	Six Months Ended June 30,
	2024		2023
Options		73,698,315		64,289,090
RSUs		2,640,115		2,738,750
PSUs		2,676,300		6,690,750
DRSUs		4,276,875		3,637,905
Convertible loan notes – Novartis		16,308,364		15,000,137
Convertible loan notes – private placement		-		24,279,659
Warrants to purchase ordinary shares		7,539,129		7,539,129
AstraZeneca milestones potentially payable in equity		1,349,692		1,349,692